BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23382200)

  • 1. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
    Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
    Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
    Jansen JH; Löwenberg B
    Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.
    Guidez F; Parks S; Wong H; Jovanovic JV; Mays A; Gilkes AF; Mills KI; Guillemin MC; Hobbs RM; Pandolfi PP; de Thé H; Solomon E; Grimwade D
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18694-9. PubMed ID: 18000064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
    Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
    Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
    Dong S; Tweardy DJ
    Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
    Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ
    Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies.
    Petti MC; Fazi F; Gentile M; Diverio D; De Fabritiis P; De Propris MS; Fiorini R; Spiriti MA; Padula F; Pelicci PG; Nervi C; Lo Coco F
    Blood; 2002 Aug; 100(3):1065-7. PubMed ID: 12130525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
    Beez S; Demmer P; Puccetti E
    PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
    Rice KL; Hormaeche I; Doulatov S; Flatow JM; Grimwade D; Mills KI; Leiva M; Ablain J; Ambardekar C; McConnell MJ; Dick JE; Licht JD
    Blood; 2009 Dec; 114(27):5499-511. PubMed ID: 19855079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
    Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
    Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
    Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.